Wednesday, November 24, 2021 Daily Archives

Five Ways the Amersham ImageQuant™ 800 GxP Helps You Remain Compliant

In highly regulated environments, such as the pharmaceutical industry, remaining GxP compliant while efficiently delivering your products to a competitive market is a challenging task, particularly when Western blot imaging is involved. While this can often be a tricky and time-consuming task, our Amersham ImageQuant™ 800 GxP imaging system and software streamlines the process. It provides simple solutions that support data traceability, accountability, and integrity. Confident decision making and GxP compliance go hand in hand with high-quality imaging. In this…

COVID-19 to shape mRNA vaccine and therapeutic sector for years to come

COVID-19 established mRNA vaccines as an effective therapeutic option and – says a technology expert – has set the blueprint for how they will be made for the foreseeable future. Developers were working on mRNA-based medicines before 2020 with Alnylam’s polyneuropathy treatment Onpattro (patisiran) being one of the first such therapies to win approval. However, the COVID-19 pandemic prompted a period of rapid growth for the market – particularly mRNA vaccines – that shows little signs of slowing according to…

Switzerland flexing its CGT muscle with a little help from Novartis and Roche

Heavy investment in R&D and manufacturing capabilities is driving the Swiss advanced therapy space but challenges including the skill-deficit still exist, says consultancy firm Coulter Partners. As interest in cell and gene therapies (CGTs) grow, certain hubs are arising globally. Philadelphia’s ‘Cellicon Valley’ and Texas both come to mind, but across the pond Switzerland has been subject to numerous investments and the sector is blossoming. “Switzerland remains a highly attractive location for biopharma in general, due to the fiscal situation,…